Safety, pharmacokinetics and antiviral activity of AHB‑137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b study
Wen Wang, Jiajia Mai, Jinlin Hou, Zhongyuan Xu, Xian Yu, Hong Ren, Xieer Liang, Yi Yang, Zhihong Liu, Hong Zhang, Shan Zhong, Yilei Wen, Tingting Lu, Haixia Cao, Xiao Qiu, Lidan Wang, Di Zhao, Miao Wang, Chengyong Yang, Guofeng Cheng, Junqi Niu, Yanhua Ding · 2026
Read Safety, pharmacokinetics and antiviral activity of AHB‑137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b study by Wen Wang, Jiajia Mai, Jinlin Hou, Zhongyuan Xu, Xian Yu, Hong Ren, Xieer Liang, Yi Yang, Zhihong Liu, Hong Zhang, Shan Zhong, Yilei Wen, Tingting Lu, Haixia Cao, Xiao Qiu, Lidan Wang, Di Zhao, Miao Wang, Chengyong Yang, Guofeng Cheng, Junqi Niu, Yanhua Ding (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13518476.txt.
Description
A short strand of synthetic RNA that silences hepatitis B's messages is through its first human tests. Wen Wang and co-authors report the phase one study of AHB-137 in this 2026 paper. Fifty-two healthy Chinese volunteers formed the safety stage. Then came twenty-two treated patients with chronic hepatitis B, whose virus was already suppressed by standard pills.
Six under-skin doses were spread over four weeks, at two dose levels. No serious harms, deaths, or dropouts occurred; most reactions were mild, sore injection sites, fever, and quiet lab blips. One patient's liver enzymes spiked as the viral surface protein fell fast, a flare the field reads with interest. Blood levels rose in proportion to dose and cleared on schedule. The study's job was safety, and the drug passed to fight another day.
Catalog record
| CREATOR | Wen Wang, Jiajia Mai, Jinlin Hou, Zhongyuan Xu, Xian Yu, Hong Ren, Xieer Liang, Yi Yang, Zhihong Liu, Hong Zhang, Shan Zhong, Yilei Wen, Tingting Lu, Haixia Cao, Xiao Qiu, Lidan Wang, Di Zhao, Miao Wang, Chengyong Yang, Guofeng Cheng, Junqi Niu, Yanhua Ding |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |